CN Patent

CN121443614A — 结晶形式

Assigned to UCB Biopharma SRL · Expires 2026-01-30 · 0y expired

What this patent protects

本文提供了式 (I) 的化合物的结晶形式，即，(7R,14R)‑11‑[2‑(1‑氨基环丁基)嘧啶‑5‑基]‑1‑(二氟甲氧基)‑6‑甲基‑6,7‑二氢‑7,14‑甲桥苯并咪唑并[1,2‑b][2,5]苯并二氮辛因‑5(14H)‑酮。还描述了包含所述结晶形式的药物组合物以及所述结晶形式和药物组合物的医学用途。 (I)

USPTO Abstract

本文提供了式 (I) 的化合物的结晶形式，即，(7R,14R)‑11‑[2‑(1‑氨基环丁基)嘧啶‑5‑基]‑1‑(二氟甲氧基)‑6‑甲基‑6,7‑二氢‑7,14‑甲桥苯并咪唑并[1,2‑b][2,5]苯并二氮辛因‑5(14H)‑酮。还描述了包含所述结晶形式的药物组合物以及所述结晶形式和药物组合物的医学用途。 (I)

Drugs covered by this patent

Patent Metadata

Patent number
CN121443614A
Jurisdiction
CN
Classification
—
Expires
2026-01-30
Drug substance claim
No
Drug product claim
No
Assignee
UCB Biopharma SRL
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.